NanoMind-GenAI is an AI-driven formulation intelligence platform that helps pharmaceutical companies, CDMOs, and R&D teams accelerate lipid nanoparticle (LNP) development for RNA therapeutics. LNP formulation currently requires hundreds to thousands of experiments over 18–24 months and can cost several million dollars, as literature, experimental design, predictive modelling, and biological interpretation remain fragmented across separate tools.
NanoMind-GenAI integrates these capabilities into a single workflow, enabling users to train and validate models on their own data and make formulation decisions through biological interpretation and evidence-backed recommendations. The platform builds on NanoMind, which has been validated on more than 1,000 synthesised LNP formulations, demonstrating predictive performance for particle size (R²=0.83) and transfection (R²=0.88).
The initial target market is the LNP CDMO sector, projected to reach USD 820 million by 2034, with an estimated near-term software opportunity of USD 20–60 million annually. Beachhead customers are mid-sized biopharma companies and specialist CDMOs without significant in-house computational infrastructure.
The project will advance the platform to TRL 5–6 through MVP development and pilot deployments with external partners. Supported by a team with strong technical and translational expertise, the project will establish the basis for commercialisation through spin-out formation and seed investment within 12 months of completion.
